LON:AKR Akers Biosciences (AKR) Share Price, News & Analysis GBX 57.50 0.00 (0.00%) (As of 03/28/2019) Add Compare Share Share Stock Analysis Stock Analysis About Akers Biosciences Stock (LON:AKR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Akers Biosciences alerts:Sign Up Key Stats Today's Range 57.50▼ 57.5050-Day Range 57.50▼ 57.5052-Week Range 23.50▼ 491.60Volume262 shsAverage Volume818 shsMarket Capitalization£21.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAkers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol 'Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth 'Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.Read More… Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Receive AKR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akers Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address AKR Stock News HeadlinesTexans vs. Vikings: RB Cam Akers makes first start since 2023September 22, 2024 | msn.comCam Akers not deterred by Achilles injuries, eyes big role for TexansAugust 20, 2024 | msn.com$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…October 21, 2024 | WealthPress (Ad)Cam Akers talks strong HOF Game performance in RB's first outing since second Achilles injuryAugust 3, 2024 | sports.yahoo.comSpringfield Police Superintendent Akers’ employment extended beyond retirement age approved by legislatureJuly 31, 2024 | msn.comAward-Winning Designer Zerina Akers Opens Luxury Fashion Rental Showroom In Los AngelesJuly 23, 2024 | msn.comTexans training camp: RB Cam Akers makes debut in HoustonJuly 23, 2024 | msn.comHouston Texans plan to sign free agent RB Cam Akers to a contractJuly 22, 2024 | msn.comSee More Headlines AKR Stock Analysis - Frequently Asked Questions How have AKR shares performed this year? Akers Biosciences' stock was trading at GBX 57.50 at the beginning of the year. Since then, AKR shares have increased by 0.0% and is now trading at GBX 57.50. View the best growth stocks for 2024 here. How do I buy shares of Akers Biosciences? Shares of AKR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Akers Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akers Biosciences investors own include SandRidge Permian Trust (PER), Rite Aid (RAD), AT&T (T), BP (BP), Cross Timbers Royalty Trust (CRT), Solbright Group (SBRT) and Workhorse Group (WKHS). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Medical Instruments & Supplies Sub-IndustryTrading Current SymbolLON:AKR CUSIPN/A CIKN/A Webwww.akersbio.com Phone+1-856-8488698FaxN/AEmployees120Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.44 Quick Ratio2.83 Sales & Book Value Annual Sales£2.32 million Price / Sales9.31 Cash FlowGBX 63.76 per share Price / Cash Flow0.90 Book ValueGBX 65.50 per share Price / Book0.88Miscellaneous Outstanding Shares37,640,000Free FloatN/AMarket Cap£21.64 million OptionableNot Optionable BetaN/A Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (LON:AKR) was last updated on 10/21/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredAfter calling a 2,269% gain, here’s his NEXT tradeReady for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredCostco gold maniaIs Gold Headed Above $3,000 per Ounce? Here's How to Play It… With so many strange events happening across ...Stansberry Research | SponsoredNotice: Major payout due November 19th - are you on the list?On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's p...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored[SHOCKING] Crypto Document Leak…The crypto market waits for no one. And my team of experts and I believe that a BIG move is right around th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akers Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Akers Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.